Anti-aging supplement manufacturer ROKIT America (RKAM.US) plans to price its IPO at $8.5-10.5 per share, aiming to raise $25 million.

Anti-aging supplement manufacturer ROKIT America announced its terms for its initial public offering (IPO) last Friday. The company plans to raise $25 million by issuing 2.6 million shares of stock, with an offering price range of $8.50 to $10.50 per share. The company plans to list on NASDAQ under the ticker symbol "RKAM". Founded in 2012, ROKIT America is headquartered in Los Angeles, California, and was spun off from ROKIT Healthcare in Korea. The company develops and sells dietary supplements focused on cellular health and anti-aging healthcare, with its core products centered around -nicotinamide mononucleotide (NMN) formulations. Its flagship products combine NMN with other ingredients such as pterostilbene and fisetin, and are sold as consumer health supplements in the US and other global markets. In addition to its supplement business, the company is also developing an AI-driven organ regeneration platform based on ROKIT Healthcare's technology, with the goal of advancing future regenerative medical applications in the Americas market. The company's products are classified as dietary supplement regulated, so they do not require pre-approval from the US Food and Drug Administration (FDA) for listing. Data shows that the company achieved $7 million in revenue in the 12 months ending on December 31, 2025.